Growing preclinical and clinical evidence suggests that the heparanase/heparan sulfate (HS) system, a crucial regulator of biological processes in the tumor and its microenvironment, might represent a valuable therapeutic target [7–11]. The gene discussed is HPSE; the disease is neoplasm.